CN102784124A - Cefuroxime axetil composition freeze-dried orally disintegrating tablets and preparation method thereof - Google Patents
Cefuroxime axetil composition freeze-dried orally disintegrating tablets and preparation method thereof Download PDFInfo
- Publication number
- CN102784124A CN102784124A CN2012103014331A CN201210301433A CN102784124A CN 102784124 A CN102784124 A CN 102784124A CN 2012103014331 A CN2012103014331 A CN 2012103014331A CN 201210301433 A CN201210301433 A CN 201210301433A CN 102784124 A CN102784124 A CN 102784124A
- Authority
- CN
- China
- Prior art keywords
- cefuroxime axetil
- oral cavity
- drying
- freeze
- composition freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 title claims abstract description 57
- 229960002620 cefuroxime axetil Drugs 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000006191 orally-disintegrating tablet Substances 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 30
- 235000019408 sucralose Nutrition 0.000 claims abstract description 11
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 7
- 108010010803 Gelatin Proteins 0.000 claims abstract description 7
- 229930195725 Mannitol Natural products 0.000 claims abstract description 7
- 229920000159 gelatin Polymers 0.000 claims abstract description 7
- 239000008273 gelatin Substances 0.000 claims abstract description 7
- 235000019322 gelatine Nutrition 0.000 claims abstract description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 7
- 239000000594 mannitol Substances 0.000 claims abstract description 7
- 235000010355 mannitol Nutrition 0.000 claims abstract description 7
- 238000004108 freeze drying Methods 0.000 claims description 49
- 210000000214 mouth Anatomy 0.000 claims description 44
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 238000003756 stirring Methods 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 16
- 239000008213 purified water Substances 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
- 239000004376 Sucralose Substances 0.000 claims description 10
- 229960001668 cefuroxime Drugs 0.000 claims description 10
- 238000011068 loading method Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- -1 cefuroxime ester Chemical class 0.000 claims description 9
- 230000008014 freezing Effects 0.000 claims description 8
- 238000007710 freezing Methods 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 abstract description 35
- 230000000694 effects Effects 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 5
- 238000010579 first pass effect Methods 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 3
- 235000019640 taste Nutrition 0.000 abstract description 2
- ZQXSFZAMFNRZOQ-UHFFFAOYSA-N 2-methylpropan-2-ol;hydrate Chemical compound O.CC(C)(C)O ZQXSFZAMFNRZOQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000006184 cosolvent Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides cefuroxime axetil composition freeze-dried orally disintegrating tablets and a preparation method of the orally disintegrating tablets, relates to the field of a medicine and a medicine preparation method technology and mainly solves the problems in the prior art that the cefuroxime axetil preparation is poor in curative effect and not suitable for children and the patients who are difficult to swallow. The cefuroxime axetil composition freeze-dried orally disintegrating tablets are prepared from the following components by weight: 25-50% of cefuroxime axetil, 25-75% of mannitol, 2-4% of gelatin, 0.1-0.15% of trichlorosucrose and 42-67% of tertiary butanol-water. The cefuroxime axetil composition freeze-dried orally disintegrating tablets prepared by the above components are easy in preparation process, and simple in components, and mainly meet the administration requirements of children and the patients who are difficult to swallow; moreover, the cefuroxime axetil composition freeze-dried orally disintegrating tablets have the advantages of being fast to disintegrate, convenient to take, and good in taste; and the tablets take effect quickly and are fully absorbed, and the first pass effect of the liver is avoided.
Description
Technical field:
The present invention relates to the method for preparing technical field of medicine and medicine, relate in particular to a kind of CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet and preparation method thereof.
Background technology:
The CEFUROXIME AXETIL chemical name is: (6R, 7R)-7-[2-furyl (methoxyimino) acetylamino]-3-carbamyl oxygen methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid, 1-acetoxyl group ethyl ester.C20H22N4O10S, molecular weight 510.48 is prone to dissolve in acetone, and is insoluble in water.Its chemical structural formula is:
CEFUROXIME AXETIL is the esterification preparation of second generation cephalosporin cefuroxime, and its effect of cefuroxime that generates is decomposed for esterase in oral back in intestinal mucosa and blood.Have has a broad antifungal spectrum, antibacterial activity is strong, and gram-positive microorganism and gram-negative micro-organism are all had good antibacterial activity, and is highly stable and side effect is little to beta-lactamase.But CEFUROXIME AXETIL is a lipophilic compound, and poorly water-soluble is met water and gathered group; Raw material is to wet, the equal instability of heat; Existing dosage form mainly contains tablet, dispersible tablet, capsule, dry suspension, and the patient that regular dosage form such as tablet and capsule etc. are not suitable for child, gerontal patient and dysphagia takes, and the little hardship of CEFUROXIME AXETIL mouthfeel, in mouth, chews to loose oral mucosa is had slight zest; Make the patient produce negation, reduced the compliance of patient's clinical application medication.
So still lack at present and press for a kind of like this cefuroxime ester formulation, its preparation technology is simple, component is simple.The oral absorption rate is high, and taking convenience, delicious is specially adapted to child, old age, is unable to leave the bed, the severely-disabled patient, and swallows inconvenient patient's medication.
Summary of the invention:
The object of the invention is to overcome the defective of prior art, need not water when a kind of taking is provided, and need not to chew; Fast CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet of disintegration rate and preparation method thereof in the oral cavity; This method preparation condition is gentle, is easy to control, is fit to industrialized great production.
For realizing the object of the invention, technical scheme realizes through following mode:
A kind of cefuroxime ester composition, the prescription of said composition is made up of principal agent and accessory drugs, and wherein principal agent is a CEFUROXIME AXETIL; Accessory drugs comprises skeleton agent, forming agent, correctives; Mannitol is selected in described skeleton agent for use, and described forming agent is selected gelatin for use, and described correctives is selected sucralose for use.
A kind of cefuroxime ester composition is characterized in that, said composition comprises following component and component quantity ratio:
The preferred ingredient quantity ratio of said each component of cefuroxime ester composition is:
Another object of the present invention provides a kind of CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet that contains above-mentioned cefuroxime ester composition.This freeze-dry orally disintegrating tablet component is simple, need not water when taking, and need not to chew; Disintegration time was no more than for 2 seconds in human oral cavity, and is rapid-action, the intestinal less residue; Absorb fully, side effect is low, and mouthfeel is good; Be particularly suitable for the infant patient and take, be prepared from following component and component quantity ratio:
The preferred ingredient quantity ratio of each component of preparation CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet is:
A further object of the present invention provides a kind of method for preparing of CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet; This method for preparing as solvent, can be accelerated the rate of sublimation of medicine with the tertiary butanol and water cosolvent, shortens lyophilization cycle; Increase dissolubility, stability, promote the crystallization of medicine.
For realizing a further object of the present invention, a kind of method for preparing of CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet adopts following technical scheme:
A) CEFUROXIME AXETIL with recipe quantity is dissolved in the tert-butyl alcohol of recipe quantity, and stirring and dissolving continues to stir at normal temperatures, preparation solution a;
B) mannitol, the sucralose with recipe quantity is dissolved in the purified water of prescription with pure water total amount 70%-80%, preparation solution b;
C) again the gelatin of recipe quantity and xanthan gum are dissolved in the purified water of prescription water consumption 20%-30%, are heated to dissolving fully, preparation solution c;
D) merge two kinds of solution that above-mentioned steps a, step b obtain and become solution d, and stir, mixed then solution is cooled to below 5 ℃;
E) mix a, two kinds of solution of d, and stir, regulate pH value to 6.0-6.5 with sodium bicarbonate;
F) according to CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet specification, confirm loading amount after, the medicinal liquid that merges is moved in the drug-containing dish by loading amount; And put into freeze drying box; Medicinal liquid is carried out freezing, (cryogenic temperature is-20 ℃--50 ℃), evacuation is dry, and (baking temperature is at 0 ℃-5 ℃; Vacuum-more than the 0.09MPa), control moisture be no more than 1.0%;
G) treat CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet drying after, in household freezer, seal;
H) cut drug-containing dish after the medicament that freezes is taken out freeze drying box, and carry out finished product packing.
Described CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet specification is 125mg/ sheet, 250mg/ sheet.
Formulated relevant monitoring method to the disintegration rate of CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet:
Disintegration
According to inspection technique disintegration (two appendix ⅹ of Chinese Pharmacopoeia version in 2010 A); The stainless steel shaft of hanging basket through the upper end hung on the metal rack; Immerse in the 1000ml beaker; And screen cloth fills temperature and is 37 ℃ ± 1 ℃ water apart from beaker bottom 25mm in the beaker when regulating the hanging basket position it being descended, when regulating height of water level hanging basket being risen screen cloth in the underwater 15mm place.
Except as otherwise herein provided, get 6 groups of test samples (every group of dosage is 250mg), put respectively in the glass tubing of above-mentioned hanging basket, add baffle plate, start disintegration tester and check, each sheet all should all disintegrates in 1.1 seconds.Result such as following table:
Dosage equates, the disintegration time and the medicine of different cefuroxime axetil tablets reach peak concentration
The disintegration rate that can find out CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet of the present invention from above experimental result is faster than CEFUROXIME AXETIL ordinary tablet.
CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet in the oral cavity, run into after the saliva can be in two seconds rapidly disintegrate, no grittiness, good mouthfeel, swallow easily, to the oral mucosa nonirritant.
The selected adjuvant of CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet all is adjuvants of suitable this tablet of preparation; Because the water solublity of CEFUROXIME AXETIL is very poor, we adopt the tertiary butanol and water cosolvent as solvent in technology, are insoluble in the CEFUROXIME AXETIL of water with tert-butyl alcohol dissolving; With other adjuvants of purified water dissolving; Both mix with suitable ratio then, are dissolved the clear and bright cosolvent of water solublity and liposoluble substance jointly, use this technology to have multiple advantage.
The first, tert-butyl alcohol freezing point is high, just can freeze at normal temperatures, with also passable after water mixes, just can solidify in the subzero several years; And tert-butyl alcohol vapour pressure is high, helps distillation, so use the tertiary butanol and water cosolvent can shorten freeze-drying time as solvent, the obtained freeze-drying product still keeps porous simultaneously.
The second, the tert-butyl alcohol and water can be with any mixed, and the medicine that will be insoluble in water like this is dissolved in the tert-butyl alcohol, can strengthen stability of drug.
The 3rd, the crystalline state that adds affiliation change water of the tert-butyl alcohol, and then the drug crystallization state that is dissolved in the water is changed, and improving freezing point, rate of sublimation improves greatly.
The 4th, tert-butyl alcohol toxicity is low, and less residue after the lyophilizing, and this just guarantees the safety of medication.
Because CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet of the present invention is main in order to satisfy child's medication demand, in prescription, has added the correctives sucralose.In traditional production application, aspartame flavour mouthfeel is pretty good, but is prone to decompose instability; Cyclamate, glucide safety receive dispute to a certain degree, and are prone to produce the back bitterness.And the sucralose sweet feel is very near sucrose, and is very stable, safe to heat, acid, alkali.Simultaneously, sucralose is not utilized by the dental caries pathogenic bacteria, can reduce pathogenic bacteria in the oral cavity, and the acid amount of generation and streptococcus cell effectively play the dental caries effect in the adhesion of dental surface, and useful especially teenager teeth is healthy; The sucralose good stability can long term storage, and in freezing dry process, can not be damaged, and is fit to industrial applications.
Advantage of the present invention:
The first, the tablet disintegrate is rapid, and drug effect is fast.CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet of the present invention is disintegrate rapidly in 2 seconds in mouth, is beneficial to the rapid stripping of medicine, shortens dissolution time, accelerates to absorb, and liver first-pass effect is little, makes its performance curative effect fast.
The second, drug absorption is abundant.CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet of the present invention is disintegrate fully in the oral cavity, makes the absorption of medicine more abundant, helps improving bioavailability of medicament like this.
Three, taking convenience, mouthfeel is good.CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet of the present invention needn't be used water delivery service, and saliva can make its complete disintegrate, and no foreign body sensation in mouthful is owing to wherein add the compliance that the sweet child of helping of suitable correctives cool taste flavor takes medicine.Compare with liquid preparation and dosage advantage accurately arranged.
Four, avoid the first pass effect of liver: because CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet of the present invention rapidly disintegrate in mouth except that major part gets into the gastrointestinal tract with swallowing act, also has the considerable part trans-oral to absorb, thereby rapid-action, first pass effect is little.
The specific embodiment:
For technological means, creation characteristic that the present invention is realized, reach purpose and effect and be easy to understand and understand, below in conjunction with specific embodiment, further set forth the present invention.
Embodiment 1
With the 125mg/ sheet is that example prepares CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet,
Prescription: 1000 amounts
The CEFUROXIME AXETIL of recipe quantity is dissolved in the tert-butyl alcohol (among the solution a) of recipe quantity, and stirring and dissolving continues to stir at normal temperatures, and mannitol, the sucralose of recipe quantity is dissolved in the purified water (solution b) of prescription with purified water total amount 70%-80%; Gelatin with recipe quantity is dissolved in the purified water (solution c) of prescription water consumption 20%-30% again, is heated to dissolving fully; Merge above-mentioned b, two kinds of solution of c are solution d, and stir, mixed then solution is cooled to below 5 ℃.Mix a, two kinds of solution of d, and stir, regulate pH to 5.5-6.5 with sodium bicarbonate; According to CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet specification, confirm loading amount after, with the medicinal liquid after merging by in the loading amount packing drug-containing dish; And put into freeze drying box, medicinal liquid is carried out freezing, treat CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet drying after; In freeze drying box, seal, take out back cutting, packing.
Embodiment 2
With the 125mg/ sheet is that example prepares CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet,
Prescription: 1000 amounts
The CEFUROXIME AXETIL of recipe quantity is dissolved in the tert-butyl alcohol (among the solution a) of recipe quantity, and stirring and dissolving continues to stir at normal temperatures, and mannitol, the sucralose of recipe quantity is dissolved in the purified water (solution b) of prescription with purified water total amount 70%-80%; Gelatin with recipe quantity is dissolved in the purified water (solution c) of prescription water consumption 20%-30% again, is heated to dissolving fully; Merge above-mentioned b, two kinds of solution of c are solution d, and stir, mixed then solution is cooled to below 5 ℃.Mix a, two kinds of solution of d, and stir, regulate pH to 5.5-6.5 with sodium bicarbonate; According to CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet specification, confirm loading amount after, with the medicinal liquid after merging by in the loading amount packing drug-containing dish; And put into freeze drying box, medicinal liquid is carried out freezing, treat CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet drying after; In freeze drying box, seal, take out back cutting, packing.
Embodiment 3
With the 125mg/ sheet is that example prepares CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet,
Prescription: 1000 amounts
The CEFUROXIME AXETIL of recipe quantity is dissolved in the tert-butyl alcohol (among the solution a) of recipe quantity, and stirring and dissolving continues to stir at normal temperatures, and mannitol, the sucralose of recipe quantity is dissolved in the purified water (solution b) of prescription with purified water total amount 70%-80%; Gelatin with recipe quantity is dissolved in the purified water (solution c) of prescription water consumption 20%-30% again, is heated to dissolving fully; Merge above-mentioned b, two kinds of solution of c are solution d, and stir, mixed then solution is cooled to below 5 ℃.Mix a, two kinds of solution of d, and stir, regulate pH to 5.5-6.5 with sodium bicarbonate; According to CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet specification, confirm loading amount after, with the medicinal liquid after merging by in the loading amount packing drug-containing dish; And put into freeze drying box, medicinal liquid is carried out freezing, treat CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet drying after; In freeze drying box, seal, take out back cutting, packing.
More than show and described ultimate principle of the present invention, principal character and advantage of the present invention.The technical staff of the industry should understand; The present invention is not restricted to the described embodiments; That describes in the foregoing description and the description is merely preference of the present invention, is not used for limiting the present invention, under the prerequisite that does not break away from spirit and scope of the invention; The present invention also has various changes and modifications, and these variations and improvement all fall in the scope of the invention that requires protection.The present invention requires protection domain to be defined by appending claims and equivalent thereof.
Claims (6)
1. a cefuroxime ester composition is characterized in that, said composition comprises following component and component quantity ratio:
2. cefuroxime ester composition according to claim 1 is characterized in that, the preferred ingredient quantity ratio of said each component of cefuroxime ester composition is:
3. a CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet that contains the said compositions of claim 1 is characterized in that, is prepared from following component and component quantity ratio:
4. CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet according to claim 3 is characterized in that, the preferred ingredient quantity ratio of each component of preparation CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet is:
5. the method for preparing of the said CEFUROXIME AXETIL composition freeze-drying of claim 3 oral cavity disintegration tablet is characterized in that the concrete steps of this method for preparing are:
A) CEFUROXIME AXETIL with recipe quantity is dissolved in the tert-butyl alcohol of recipe quantity, and stirring and dissolving continues to stir at normal temperatures, preparation solution a;
B) mannitol, the sucralose with recipe quantity is dissolved in the purified water of prescription with pure water total amount 70%-80%, preparation solution b;
C) again the gelatin of recipe quantity and xanthan gum are dissolved in the purified water of prescription water consumption 20%-30%, are heated to dissolving fully, preparation solution c;
D) merge two kinds of solution that above-mentioned steps a, step b obtain and become solution d, and stir, mixed then solution is cooled to below 5 ℃;
E) mix a, two kinds of solution of d, and stir, regulate pH value to 6.0-6.5 with sodium bicarbonate;
F) according to CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet specification, confirm loading amount after, the medicinal liquid that merges is moved in the drug-containing dish by loading amount, and puts into freeze drying box, to medicinal liquid carry out freezing, evacuation is dry, the control moisture is no more than 1.0%;
G) treat CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet drying after, in household freezer, seal;
H) cut drug-containing dish after the medicament that freezes is taken out freeze drying box, and carry out finished product packing.
6. the method for preparing of CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet according to claim 5 is characterized in that: described CEFUROXIME AXETIL composition freeze-drying oral cavity disintegration tablet specification is 125mg/ sheet, 250mg/ sheet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103014331A CN102784124A (en) | 2012-08-23 | 2012-08-23 | Cefuroxime axetil composition freeze-dried orally disintegrating tablets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103014331A CN102784124A (en) | 2012-08-23 | 2012-08-23 | Cefuroxime axetil composition freeze-dried orally disintegrating tablets and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102784124A true CN102784124A (en) | 2012-11-21 |
Family
ID=47149846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012103014331A Pending CN102784124A (en) | 2012-08-23 | 2012-08-23 | Cefuroxime axetil composition freeze-dried orally disintegrating tablets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102784124A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546765A (en) * | 2014-12-25 | 2015-04-29 | 海南卫康制药(潜山)有限公司 | Cefuroxime composition freeze-dried tablet and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005018618A1 (en) * | 2003-08-23 | 2005-03-03 | Korea United Pharm, Inc | Formulation of stable for moisture absorption and quickly dissolved tablet containing cefuroxime axetil and it's manufacturing process |
| CN1689649A (en) * | 2004-04-30 | 2005-11-02 | 量子高科（北京）研究院有限公司 | Oral cavity quick dissolving preparation and production method thereof |
| CN102579378A (en) * | 2012-02-07 | 2012-07-18 | 海南卫康制药(潜山)有限公司 | Child cefdinir composition freeze-dried oral disintegrating tablet and preparation method thereof |
| CN102614138A (en) * | 2011-01-26 | 2012-08-01 | 量子高科（北京）研究院有限公司 | Oral disintegrating tablet and preparation method thereof |
-
2012
- 2012-08-23 CN CN2012103014331A patent/CN102784124A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005018618A1 (en) * | 2003-08-23 | 2005-03-03 | Korea United Pharm, Inc | Formulation of stable for moisture absorption and quickly dissolved tablet containing cefuroxime axetil and it's manufacturing process |
| CN1689649A (en) * | 2004-04-30 | 2005-11-02 | 量子高科（北京）研究院有限公司 | Oral cavity quick dissolving preparation and production method thereof |
| CN102614138A (en) * | 2011-01-26 | 2012-08-01 | 量子高科（北京）研究院有限公司 | Oral disintegrating tablet and preparation method thereof |
| CN102579378A (en) * | 2012-02-07 | 2012-07-18 | 海南卫康制药(潜山)有限公司 | Child cefdinir composition freeze-dried oral disintegrating tablet and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546765A (en) * | 2014-12-25 | 2015-04-29 | 海南卫康制药(潜山)有限公司 | Cefuroxime composition freeze-dried tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102579378B (en) | Child cefdinir composition freeze-dried oral disintegrating tablet and preparation method thereof | |
| CN102525978B (en) | Children amoxicillin-potassium clavulanate composition | |
| CN102631336B (en) | Freeze-drying orally disintegrating tablet with vitamin K1 composition for infants and preparation method for freeze-drying orally disintegrating tablet | |
| CN102600119B (en) | Pediatric acetaminophen composition | |
| CN102772383A (en) | Azithromycin composition freeze-dried orally disintegrating tablet and preparation method thereof | |
| CN102784119A (en) | Roxithromycin composition freeze-dried orally disintegrating tablets and preparation method thereof | |
| CN104490925A (en) | Vitamin D calcium composition chewable tablets and preparation method thereof | |
| CN102784124A (en) | Cefuroxime axetil composition freeze-dried orally disintegrating tablets and preparation method thereof | |
| CN102525979B (en) | Infant ibuprofen composition | |
| CN102784121A (en) | Levofloxacin composition freeze-dried orally disintegrating tablets and preparation method thereof | |
| CN102525980B (en) | Children cetirizine hydrochloride composition | |
| CN102648899B (en) | Child cefalexin composition | |
| CN102614212B (en) | Freeze-dried orally disintegrating tablets of pediatric ribavirin composition, and preparation method thereof | |
| CN102784125A (en) | Cefetamet pivoxil composition freeze-dried orally disintegrating tablet and preparation method thereof | |
| CN102940610A (en) | Vitamin B6 composition freeze-drying orally disintegrating tablets and preparation method thereof | |
| CN105250227A (en) | Citric acid caffeine freeze-dried powder and preparation method thereof | |
| CN102784118A (en) | Fosfomycin calcium composition freeze-dried orally disintegrating tablets and preparation method thereof | |
| CN102600153B (en) | Pediatric compound anisodamine hydrobromide and chlorpheniramine maleate freeze-dried orally disintegrating tablets and manufacturing method thereof | |
| CN104490814A (en) | Zinc gluconate composition chewable tablets and preparation method thereof | |
| CN102784122A (en) | Isoniazid composition freeze-dried orally disintegrating tablet and preparation method thereof | |
| CN103239478A (en) | Calcium carbonate milk composition freeze-dried orally disintegrating tablets, and preparation method thereof | |
| CN102784117A (en) | Gentamicin sulfate composition freeze-dried orally disintegrating tablet and preparation method thereof | |
| CN102784123A (en) | Diclofenac sodium composition freeze-dried orally disintegrating tablets and preparation method thereof | |
| CN103284964A (en) | Children zinc gluconate-milk composition freeze-dried oral disintegrating tablet and preparation method thereof | |
| CN102784126A (en) | Rifampicin composition freeze-dried orally disintegrating tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121121 |